AACR Virtual Meeting: COVID-19 and Cancer; July 20-22, 2020 Significant variations in experience of the COVID-19 pandemic have been observed in the United States. Increased risk of COVID-19-related death has been reported among cancer survivors, but due to limited sample size in those studies, to what extent the previous cancer diagnosis may play a role in the determination of COVID-19-related death is still unclear. In this study, using aggregated real-world data extracted from TriNetx electronic medical record data from 34 hospitals around United States, we assessed the relationship between prior cancer diagnosis in the past 5 years and COVID-19-related death within one month after the diagnosis of virus contraction. A total of 24,534 patients aged 18-80 years old who contracted COVID-19 were identified from January 20th to May 4th, 2020. Among them, 3,619 were cancer survivors. In the univariate analysis, we found that cancer patients had 2.55-fold increased risk ratio (RR) of death than those without cancer (RR=2.55, 95% Confidence Interval (CI): 2.25, 2.88), although the risk was decreased but still significant (RR=1.42, 95% CI: 1.21, 1.67) after adjustment for demographics (e.g., age, gender, and race) and other pre-existing chronic diseases, including obesity, diabetes, hypertension, chronic ischemic heart disease, chronic kidney disease, asthma, and COPD. When stratified by cancer sites, significant associations were observed between respiratory and intrathoracic, oral, digestive, breast, male genital, urinary, blood, and skin cancers with COVID-19-related death in the univariate analysis. As expected, the most significant cancer site was respiratory and intrathoracic cancer with an RR of 6.49 (95% CI: 5.21, 8.07). However, after adjustment for demographics and other pre-existing chronic diseases, the significant associations remained for respiratory and intrathoracic, digestive, and blood cancers (RR=1.89, 95% CI: 1.31, 2.73; RR=1.59, 95% CI: 1.06, 2.38; RR=2.08, 95% CI: 1.51, 2.86, respectively). In addition, among cancer survivors, men were found to have higher RR of death than women (RR=1.41, 95% CI: 1.12, 1.78), but the RR did not differ between Blacks and Whites. In summary, our data show significant increased COVID-19-related death among cancer survivors. The elevated risk was particularly evident among those who had respiratory and intrathoracic, digestive, and blood cancers. Citation Format: Jie Shen, Hua Zhao. Increased risk of COVID-19-related death among cancer survivors [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S10-03.

中文翻译：

---

摘要S10-03：癌症幸存者中COVID-19相关死亡风险增加

AACR虚拟会议：COVID-19和癌症；2020年7月20日至22日，在美国观察到了COVID-19大流行经验的重大变化。据报道，癌症幸存者中与COVID-19相关的死亡风险增加，但是由于这些研究的样本量有限，先前的癌症诊断在确定COVID-19相关的死亡中可能发挥何种作用尚不清楚。在这项研究中，使用从美国34家医院的TriNetx电子病历数据中提取的汇总真实数据，我们评估了过去5年中先前的癌症诊断与诊断后一个月内与COVID-19相关的死亡之间的关系。病毒收缩。从2020年1月20日至5月4日，共发现24534例年龄在18-80岁之间的患者，他们感染了COVID-19。其中3,619名癌症幸存者。在单变量分析中，我们发现癌症患者的死亡风险比（RR）比无癌症的患者高2.55倍（RR = 2.55，95％可信区间（CI）：2.25，2.88），尽管风险有所降低，但在调整了人口统计数据（例如年龄，性别和种族）和其他先前存在的慢性病（包括肥胖症，糖尿病，高血压，慢性缺血性心脏病，慢性病）后，仍显着（RR = 1.42，95％CI：1.21、1.67）肾脏疾病，哮喘和COPD。当按癌症部位分层时，在单变量分析中观察到呼吸道和胸腔内，口腔，消化道，乳腺癌，男性生殖器，泌尿，血液和皮肤癌与COVID-19相关的死亡之间存在显着关联。不出所料 最重要的癌症部位是呼吸道和胸腔内癌，RR为6.49（95％CI：5.21，8.07）。但是，在调整了人口统计学特征和其他先前存在的慢性疾病后，呼吸道和胸腔内，消化道和血液癌症的相关性仍然很显着（RR = 1.89，95％CI：1.31、2.73； RR = 1.59，95％CI：1.06 ，2.38； RR = 2.08、95％CI：分别为1.51、2.86）。此外，在癌症幸存者中，发现男性的死亡率比女性高（RR = 1.41，95％CI：1.12，1.78），但是黑人和白人之间的RR没有差异。总之，我们的数据显示癌症幸存者中与COVID-19相关的死亡显着增加。在患有呼吸道和胸腔内，消化道和血液癌症的患者中，升高的风险尤为明显。引用格式：沉洁，赵华。癌症幸存者中与COVID-19相关的死亡风险增加[摘要]。在：AACR虚拟会议录：COVID-19和癌症；2020年7月20-22日。费城（PA）：AACR；Clin Cancer Res 2020; 26（18_Suppl）：摘要编号S10-03。